N
Nanjing King-friend Biochemical Pharmaceutical Co Ltd
SSE:603707
Nanjing King-friend Biochemical Pharmaceutical Co Ltd
SSE:603707
Price:
14
CNY
-1.41%
Market Closed
Market Cap:
22.6B
CNY
Add
Note
Why Create Notes?
Capture your thoughts
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Peter Lynch
Track and Analyze Performance
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Continuous Learning and Adaptation
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
Boost Decision Confidence
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Delete Note
Do you really want to delete this note?
This action cannot be undone.
Alert
Nanjing King-friend Biochemical Pharmaceutical Co Ltd
14
-0.2 (-1.41%)
| 52 Week Range |
10.7
16.24
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
Delete Alert
This alert will be permanently deleted.
Ask me anything about
Nanjing King-friend Biochemical Pharmaceutical Co Ltd
Income Statement
Earnings Waterfall
Nanjing King-friend Biochemical Pharmaceutical Co Ltd
Nanjing King-friend Biochemical Pharmaceutical Co Ltd
|
Revenue
|
3.9B
CNY
|
|
Cost of Revenue
|
-2.3B
CNY
|
|
Gross Profit
|
1.6B
CNY
|
|
Operating Expenses
|
-2B
CNY
|
|
Operating Income
|
-392m
CNY
|
|
Other Expenses
|
-30.9m
CNY
|
|
Net Income
|
-423m
CNY
|
Income Statement
Nanjing King-friend Biochemical Pharmaceutical Co Ltd
Nanjing King-friend Biochemical Pharmaceutical Co Ltd
Currency: CNY
| Jun-2017 | Sep-2017 | Dec-2017 | Mar-2018 | Jun-2018 | Sep-2018 | Dec-2018 | Mar-2019 | Jun-2019 | Sep-2019 | Dec-2019 | Mar-2020 | Jun-2020 | Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | |||||||||||||||||||||||||||||||
| Revenue |
758
N/A
|
915
+21%
|
1 113
+22%
|
1 325
+19%
|
1 479
+12%
|
1 633
+10%
|
1 700
+4%
|
1 875
+10%
|
2 027
+8%
|
2 224
+10%
|
2 470
+11%
|
2 594
+5%
|
2 689
+4%
|
2 800
+4%
|
2 915
+4%
|
3 064
+5%
|
3 270
+7%
|
3 537
+8%
|
3 687
+4%
|
3 980
+8%
|
3 911
-2%
|
3 758
-4%
|
3 713
-1%
|
3 844
+4%
|
4 041
+5%
|
4 004
-1%
|
3 931
-2%
|
3 628
-8%
|
3 770
+4%
|
3 877
+3%
|
|
| Gross Profit | |||||||||||||||||||||||||||||||
| Cost of Revenue |
(438)
|
(504)
|
(597)
|
(716)
|
(771)
|
(850)
|
(860)
|
(945)
|
(1 008)
|
(1 092)
|
(1 204)
|
(1 213)
|
(1 176)
|
(1 186)
|
(1 236)
|
(1 251)
|
(1 392)
|
(1 523)
|
(1 603)
|
(1 834)
|
(1 826)
|
(1 796)
|
(1 778)
|
(1 866)
|
(2 024)
|
(2 042)
|
(3 272)
|
(2 047)
|
(2 194)
|
(2 288)
|
|
| Gross Profit |
320
N/A
|
411
+29%
|
516
+26%
|
609
+18%
|
707
+16%
|
784
+11%
|
840
+7%
|
929
+11%
|
1 019
+10%
|
1 132
+11%
|
1 265
+12%
|
1 380
+9%
|
1 513
+10%
|
1 614
+7%
|
1 679
+4%
|
1 813
+8%
|
1 879
+4%
|
2 013
+7%
|
2 083
+3%
|
2 146
+3%
|
2 085
-3%
|
1 961
-6%
|
1 935
-1%
|
1 977
+2%
|
2 017
+2%
|
1 962
-3%
|
659
-66%
|
1 581
+140%
|
1 576
0%
|
1 590
+1%
|
|
| Operating Income | |||||||||||||||||||||||||||||||
| Operating Expenses |
(112)
|
(113)
|
(175)
|
(203)
|
(259)
|
(325)
|
(390)
|
(440)
|
(503)
|
(557)
|
(594)
|
(637)
|
(684)
|
(733)
|
(758)
|
(811)
|
(812)
|
(843)
|
(854)
|
(839)
|
(834)
|
(822)
|
(913)
|
(929)
|
(990)
|
(905)
|
(1 041)
|
(2 070)
|
(2 008)
|
(1 982)
|
|
| Selling, General & Administrative |
(112)
|
(112)
|
(87)
|
(179)
|
(237)
|
(265)
|
(283)
|
(347)
|
(377)
|
(419)
|
(420)
|
(465)
|
(493)
|
(541)
|
(551)
|
(592)
|
(582)
|
(604)
|
(614)
|
(597)
|
(603)
|
(592)
|
(611)
|
(641)
|
(671)
|
(580)
|
(597)
|
(510)
|
(468)
|
(472)
|
|
| Research & Development |
0
|
0
|
(77)
|
(25)
|
0
|
(59)
|
(90)
|
(87)
|
(125)
|
(138)
|
(148)
|
(178)
|
(187)
|
(189)
|
(143)
|
(174)
|
(188)
|
(197)
|
(183)
|
(241)
|
(231)
|
(229)
|
(219)
|
(278)
|
(309)
|
(315)
|
(321)
|
(380)
|
(396)
|
(376)
|
|
| Depreciation & Amortization |
0
|
0
|
(11)
|
0
|
0
|
0
|
(17)
|
0
|
0
|
0
|
(25)
|
0
|
0
|
0
|
(61)
|
0
|
0
|
0
|
(55)
|
0
|
0
|
0
|
(82)
|
0
|
0
|
0
|
(73)
|
0
|
0
|
0
|
|
| Other Operating Expenses |
(1)
|
(1)
|
(0)
|
1
|
(23)
|
(1)
|
(1)
|
(6)
|
(1)
|
1
|
(1)
|
6
|
(4)
|
(4)
|
(3)
|
(45)
|
(42)
|
(42)
|
(2)
|
(1)
|
(0)
|
(1)
|
(2)
|
(10)
|
(10)
|
(10)
|
(50)
|
(1 181)
|
(1 145)
|
(1 134)
|
|
| Operating Income |
208
N/A
|
298
+44%
|
341
+14%
|
406
+19%
|
448
+10%
|
459
+2%
|
451
-2%
|
489
+9%
|
517
+6%
|
576
+11%
|
672
+17%
|
744
+11%
|
829
+11%
|
880
+6%
|
921
+5%
|
1 002
+9%
|
1 067
+6%
|
1 170
+10%
|
1 229
+5%
|
1 307
+6%
|
1 251
-4%
|
1 140
-9%
|
1 021
-10%
|
1 048
+3%
|
1 028
-2%
|
1 057
+3%
|
(382)
N/A
|
(489)
-28%
|
(432)
+12%
|
(392)
+9%
|
|
| Pre-Tax Income | |||||||||||||||||||||||||||||||
| Interest Income Expense |
6
|
13
|
12
|
19
|
17
|
8
|
10
|
1
|
7
|
6
|
(4)
|
(11)
|
(25)
|
(40)
|
(44)
|
(56)
|
(22)
|
(1)
|
(46)
|
(41)
|
29
|
132
|
153
|
117
|
148
|
2
|
87
|
14
|
(126)
|
(132)
|
|
| Non-Reccuring Items |
0
|
0
|
0
|
(0)
|
0
|
0
|
(0)
|
(0)
|
(0)
|
0
|
0
|
0
|
0
|
(0)
|
(0)
|
0
|
(0)
|
(0)
|
(1)
|
0
|
(1)
|
(1)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
|
| Gain/Loss on Disposition of Assets |
0
|
(0)
|
(0)
|
0
|
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
0
|
0
|
0
|
|
| Total Other Income |
5
|
4
|
4
|
4
|
5
|
6
|
7
|
12
|
12
|
11
|
13
|
9
|
11
|
31
|
38
|
47
|
47
|
23
|
22
|
13
|
2
|
8
|
12
|
12
|
33
|
33
|
(0)
|
(1)
|
(15)
|
(20)
|
|
| Pre-Tax Income |
218
N/A
|
314
+44%
|
356
+13%
|
429
+20%
|
470
+10%
|
473
+1%
|
468
-1%
|
502
+7%
|
535
+7%
|
593
+11%
|
680
+15%
|
741
+9%
|
815
+10%
|
871
+7%
|
915
+5%
|
993
+9%
|
1 091
+10%
|
1 193
+9%
|
1 204
+1%
|
1 280
+6%
|
1 280
+0%
|
1 278
0%
|
1 185
-7%
|
1 177
-1%
|
1 208
+3%
|
1 092
-10%
|
(295)
N/A
|
(476)
-61%
|
(573)
-20%
|
(545)
+5%
|
|
| Net Income | |||||||||||||||||||||||||||||||
| Tax Provision |
(25)
|
(38)
|
(42)
|
(49)
|
(52)
|
(48)
|
(43)
|
(50)
|
(49)
|
(55)
|
(74)
|
(80)
|
(91)
|
(104)
|
(118)
|
(127)
|
(147)
|
(160)
|
(140)
|
(159)
|
(157)
|
(155)
|
(99)
|
(89)
|
(111)
|
(71)
|
105
|
131
|
164
|
122
|
|
| Income from Continuing Operations |
193
|
276
|
314
|
380
|
418
|
425
|
425
|
452
|
487
|
539
|
606
|
661
|
724
|
767
|
797
|
866
|
944
|
1 033
|
1 064
|
1 121
|
1 123
|
1 123
|
1 087
|
1 088
|
1 098
|
1 021
|
(189)
|
(345)
|
(409)
|
(423)
|
|
| Income to Minority Interest |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(1)
|
(1)
|
0
|
3
|
10
|
9
|
9
|
5
|
(5)
|
(5)
|
(5)
|
(2)
|
4
|
5
|
4
|
2
|
0
|
0
|
0
|
0
|
|
| Net Income (Common) |
193
N/A
|
276
+43%
|
314
+14%
|
380
+21%
|
418
+10%
|
425
+2%
|
425
0%
|
452
+6%
|
487
+8%
|
539
+11%
|
605
+12%
|
660
+9%
|
724
+10%
|
770
+6%
|
806
+5%
|
875
+9%
|
953
+9%
|
1 038
+9%
|
1 059
+2%
|
1 116
+5%
|
1 118
+0%
|
1 122
+0%
|
1 091
-3%
|
1 093
+0%
|
1 101
+1%
|
1 023
-7%
|
(189)
N/A
|
(345)
-82%
|
(409)
-19%
|
(423)
-3%
|
|
| EPS (Diluted) |
0.23
N/A
|
0.32
+39%
|
0.37
+16%
|
0.42
+14%
|
0.45
+7%
|
0.46
+2%
|
0.46
N/A
|
0.49
+7%
|
0.53
+8%
|
0.58
+9%
|
0.65
+12%
|
0.71
+9%
|
0.78
+10%
|
0.83
+6%
|
0.86
+4%
|
0.93
+8%
|
0.6
-35%
|
0.61
+2%
|
0.68
+11%
|
0.7
+3%
|
0.69
-1%
|
0.7
+1%
|
0.67
-4%
|
0.68
+1%
|
0.68
N/A
|
0.63
-7%
|
-0.12
N/A
|
-0.21
-75%
|
-0.25
-19%
|
-0.25
N/A
|
|
Switch to:
Switch to:
See Also
Discover More
You don't have any saved screeners yet
